858 Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.8five8tx.com
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1
Recruiting
- Conditions
- Prostate CancerCastrate Resistant Prostate CancerBRCA MutationEndometrial CancerColorectal CancerGastric CancerAdvanced or Metastatic Solid TumorsOvarian CancerBRCA2 MutationBRCA1 Mutation
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- 858 Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06395519
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath